REFERENCES

Benedict K, Park BJ 2014 Invasive fungal infections after natural disasters. Emerg Infect Dis J 20: 349-355

Carpenter M, Polk C, Castellani R, Mochoruk K, Sanche S, Stern B, Donnenberg MS 2007 Encephalitis of the basal ganglia in an injection drug user. Clin Infect Dis. 45:1479, 1522-1524

Gade L, Hurst S, Balajee SA, Lockhart SR, Litvintseva AP 2017.Detection of mucormycetes and other pathogenic fungi in formalin fixed paraffin embedded and fresh tissues using the extended region of 28S rDNA. Med Mycol55: 385-395

Ibrahim AS, Spellberg B, Edwards J Jr. 2008 Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis 21:620-625

Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR 2016 Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis 16:730. PubMed PMID: 27905900

Reiss E, Shadomy HS, Lyon III, GM 2011 Fundamental Medical Mycology John Wiley and Sons. Hoboken NJ 624 p

Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP 2018 Therapy of mucormycosis. J Fungi (Basel); 4(3). pii: E90. doi: 10.3390/jof4030090

Springer J, McCormick Smith I, Hartmann S, Winkelmann R, Wilmes D, Cornely O, Kessel J, Löffler J, Rickerts V 2018 Identification of Aspergillus and Mucorales in formalin-fixed, paraffin-embedded tissue samples: Comparison of specific and broad-range fungal qPCR assays. Med Mycol. Jun 19. doi: 10.1093/mmy/myy041. [Epub ahead of print]

Sun H-Y, Singh N 2011 Mucormycosis: its contemporary face and management strategies. Lancet Infect Dis 13:301-311